Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 alone or with cadonilimab for advanced solid tumors including well/dedifferentiated liposarcoma
ChiCTR2300075521Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SPH4336 and cadonilimab in well-differentiated liposarcoma (WDLS), Liposarcoma and Nonhematologic neoplasms (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Tolerance in dose reduction stage and Progression-free survival. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
SPH4336cadonilimab
03
Conditions
well-differentiated liposarcoma (WDLS)LiposarcomaNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2300075521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075521.